广济药业：关于取得甲钴胺片药品注册证书的公告

Core Viewpoint - Guangji Pharmaceutical has received approval from the National Medical Products Administration for its Mecobalamin tablets, indicating a significant advancement in its product offerings for the treatment of peripheral neuropathy [1] Group 1: Product Approval - The company announced the receipt of the drug registration certificate for Mecobalamin tablets, with a specification of 10 tablets per board and 2 boards per box [1] - The registration classification for the product is categorized as a Class 4 chemical drug, with the approval number being Guoyao Zhunzi H20263341 [1] - This approval is expected to enhance the company's portfolio in the pharmaceutical market, particularly in the area of peripheral nerve disease treatment [1]